Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.

Yanai S, Nakamura S, Kawasaki K, Toya Y, Akasaka R, Oizumi T, Ishida K, Sugai T, Matsumoto T.

Dig Endosc. 2019 Oct 9. doi: 10.1111/den.13555. [Epub ahead of print]

PMID:
31595568
2.

Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.

Wang Y, Abu-Sbeih H, Mao E, Ali N, Qiao W, Trinh VA, Zobniw C, Johnson DH, Samdani R, Lum P, Shuttlesworth G, Blechacz B, Bresalier R, Miller E, Thirumurthi S, Richards D, Raju G, Stroehlein J, Diab A.

Inflamm Bowel Dis. 2018 Jul 12;24(8):1695-1705. doi: 10.1093/ibd/izy104.

PMID:
29718308
3.

Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis.

Verschuren EC, van den Eertwegh AJ, Wonders J, Slangen RM, van Delft F, van Bodegraven A, Neefjes-Borst A, de Boer NK.

Clin Gastroenterol Hepatol. 2016 Jun;14(6):836-842. doi: 10.1016/j.cgh.2015.12.028. Epub 2015 Dec 31.

PMID:
26748223
4.

Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis.

Wang DY, Ye F, Zhao S, Johnson DB.

Oncoimmunology. 2017 Jul 5;6(10):e1344805. doi: 10.1080/2162402X.2017.1344805. eCollection 2017.

5.

Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis.

Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y.

J Immunother Cancer. 2018 Sep 25;6(1):95. doi: 10.1186/s40425-018-0411-1.

6.

Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis.

Adler BL, Pezhouh MK, Kim A, Luan L, Zhu Q, Gani F, Yarchoan M, Chen J, Voltaggio L, Parian A, Lazarev M, Lauwers GY, Pawlik TM, Montgomery EA, Jaffee E, Le DT, Taube JM, Anders RA.

J Intern Med. 2018 Jun;283(6):568-577. doi: 10.1111/joim.12744. Epub 2018 Mar 24.

7.

[A case of severe colitis caused by immune checkpoint inhibitor].

Kanamori H, Yasuhara H, Mashima S, Suto K, Yamauchi K, Akita M, Jinno H, Hata H, Nakatsu M, Ando M.

Nihon Shokakibyo Gakkai Zasshi. 2019;116(3):235-240. doi: 10.11405/nisshoshi.116.235. Japanese.

PMID:
30853676
8.

A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine.

Kikuchi H, Sakuraba H, Akemoto Y, Murai Y, Fukutoku Y, Asari T, Tatsuta T, Hasui K, Hiraga H, Sawaya M, Chinda D, Mikami T, Tanaka M, Fukuda S.

Immunol Med. 2019 Mar;42(1):39-44. doi: 10.1080/25785826.2019.1580477. Epub 2019 Mar 27.

PMID:
30917094
9.

Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.

Chatzinasiou F, Polymeros D, Panagiotou M, Theodoropoulos K, Rigopoulos D.

Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.

PMID:
27149138
10.

Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment.

Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP.

Oncologist. 2018 Oct;23(10):1236-1241. doi: 10.1634/theoncologist.2017-0375. Epub 2018 May 16.

11.

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study.

Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, Richards DM, Charabaty A, Wang Y.

J Immunother Cancer. 2018 Dec 5;6(1):142. doi: 10.1186/s40425-018-0461-4.

12.

Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer.

Yasuda Y, Urata Y, Tohnai R, Ito S, Kawa Y, Kono Y, Hattori Y, Tsuda M, Sakuma T, Negoro S, Satouchi M.

Intern Med. 2018 May 1;57(9):1269-1272. doi: 10.2169/internalmedicine.9230-17. Epub 2017 Dec 27.

13.

Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report.

Nassri AB, Muenyi V, AlKhasawneh A, Ribeiro BS, Scolapio JS, Malespin M, de Melo SW Jr.

World J Gastrointest Pharmacol Ther. 2019 Jan 21;10(1):29-34. doi: 10.4292/wjgpt.v10.i1.29.

14.

Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike-report of new cases and review of the literature.

Cañete F, Mañosa M, Lobatón T, Mesonero F, Rodríguez-Lago I, Cabré E, Cabriada JL, López-Sanromán A, Domènech E.

Int J Colorectal Dis. 2019 May;34(5):861-865. doi: 10.1007/s00384-019-03268-4. Epub 2019 Mar 3. Review.

PMID:
30826963
15.

Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy.

Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A, Pelayo E, Beach M, Gulley JL, Madan RA, Feliciano J, Grisius M, Long L, Powers A, Kleiner DE, Cappelli L, Alevizos I.

Oncologist. 2019 Sep;24(9):1259-1269. doi: 10.1634/theoncologist.2018-0823. Epub 2019 Apr 17.

16.

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.

Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J.

BMJ. 2018 Nov 8;363:k4226. doi: 10.1136/bmj.k4226.

17.

A case of checkpoint inhibitor-induced celiac disease.

Alsaadi D, Shah NJ, Charabaty A, Atkins MB.

J Immunother Cancer. 2019 Aug 5;7(1):203. doi: 10.1186/s40425-019-0694-x.

18.

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.

Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, Busaidy NL, Subudhi SK, Diab A, Dadu R.

Thyroid. 2018 Oct;28(10):1243-1251. doi: 10.1089/thy.2018.0116.

19.

An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.

Miyahara K, Noda T, Ito Y, Hidaka H, Fujimoto S, Takedomi H, Akutagawa T, Sakata Y, Shimamura T, Tominaga N, Yamaguchi D, Fujimoto K.

Digestion. 2020;101(1):60-65. doi: 10.1159/000504647. Epub 2019 Dec 4.

PMID:
31801131
20.

Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis.

Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AP, Okhuysen PC, Jenq RR, Wang Y.

J Immunother Cancer. 2019 Sep 5;7(1):242. doi: 10.1186/s40425-019-0714-x. Erratum in: J Immunother Cancer. 2019 Dec 17;7(1):352.

Supplemental Content

Support Center